Skin and Connective Tissue Diseases

445 trials 165 recruiting

Filter these 445 trials by phase, country and sponsor.

Open in Search →

A phase 3b, interventional, adaptive, clinical trial to evaluate the efficacy and safety of tralokinumab 300 mg every second week monotherap… Ended

2022-502653-34-01 Atopic dermatitis and moderate-to severe atopic hand ec 11 2024-05-30
A study to evaluate the efficacy and safety of subcutaneous amlitelimab monotherapy compared with placebo in participants aged 12 years and … Ended

2022-501196-41-00 Dermatitis atopic 5 2024-05-29
A study to evaluate the efficacy and safety of subcutaneous amlitelimab monotherapy compared with placebo in participants aged 12 years and … Ended

2023-506557-38-00 Dermatitis atopic 5 2024-05-16
A Study to Evaluate the Safety and Effectiveness of ADX-914 in Subjects with Moderate to Severe Atopic Dermatitis Ended

2023-510238-10-00 Moderate to Severe Atopic Dermatitis 4 2024-05-13
An open label, randomized, two-period, two-sequence, crossover bioavailability study to assess the pharmacokinetic and safety profile of Val… Ended

2024-511570-77-00 not applicable (submitted trial is a bioavailability st 2 2024-05-13
AN OPEN-LABEL, RANDOMIZED, SINGLE DOSE, TWO-STAGE CROSSOVER ADAPTIVE BIOEQUIVALENCE STUDY OF TRIAMCINOLONE ACETONIDE 40 MG/ML STERILE INJECT… Ended

2023-509399-40-00 Intramuscular administration of triamcinolone acetonide 2 2024-05-09
A Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-279 With a Randomized Withdrawal and Retreatment Period in Subject… Ended

2023-505842-24-00 Moderate to Severe Plaque Psoriasis 5 2024-05-07
Clinical efficacy and safety of sequential therapy with cryotherapy and topical tirbanibulin 1% in actinic keratoses in transplant recipient… Ended

2023-508091-11-00 Actinic keratosis 11 2024-05-06
Efficacy and Safety of ANB032 in the Treatment of Subjects with Atopic Dermatitis Ended

2023-503522-40-01 Atopic Dermatitis 4 2024-04-10
A Phase 2b, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Dose Finding study to evaluate the Efficacy, Safety, Pharmacokinet… Ended

2023-505414-15-00 Dermatitis, Atopic 4 2024-04-10
A Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-279 in Subjects With Moderate-to-Severe Plaque Psoriasis Ended

2023-505841-22-00 Moderate to Severe Plaque Psoriasis 5 2024-04-04
A Phase 1b/2a, Dose Escalation Trial of Safety, Pharmacokinetic/Pharmacodynamic and Preliminary Clinical Activity of Briquilimab in Adult Pa… Ended

2023-507534-24-00 Chronic Inducible Urticaria 9 2024-03-06
Double-Blind, Randomized, Placebo-Controlled, Phase 1b, Pharmacodynamic Trial of TEV-56192 Following a Single Intravenous Administration in … Ended

2023-507018-29-00 Pruritus 3 2024-03-05
Effects of a new topical treatment, Victorhy, in patients with severe hand hyperhidrosis Ended

2023-507114-27-00 Severe primary hand hyperhidrosis 4 2024-02-28
This is a clinical trial (study), to be conducted at multiple clinical sites, of an oral study drug (EP262) that will be investigated in adu… Ended

2023-504800-28-00 Chronic Inducible Urticaria 3 2024-02-23
This is a clinical trial (study), to be conducted at multiple clinical sites, of an oral study drug (EP262) that will be investigated in adu… Ended

2023-504799-94-00 Chronic Spontaneous Urticaria 4 2024-02-20
A Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis Ended

2022-502461-23-00 Prurigo Nodularis 5 2024-02-15
Phase 2 study of SAR444656 in adult participants with moderate to severe atopic dermatitis. Ended

2023-504346-66-00 Dermatitis atopic 4 2024-02-14
Single-dose Study of BMS-986326 at Two Dose Levels in Participants with Atopic Dermatitis Ended

2022-502997-18-00 Atopic Dermatitis 3 2024-02-02
Randomised, crossover bioavailability clinical trial of oral minoxidil 1 mg, after single and multiple dose administration to healthy volunt… Ended

2023-503796-14-00 Androgenetic alopecia 3 2024-02-01
A Study to Learn How Different Manufactured Products of the Study Medicine Called Ritlecitinib are Taken up Into the Blood in Healthy Adults… Ended

2023-505603-23-00 ulcerative colitis, Crohn’s Disease, alopecia areata, r 3 2024-01-29
Extending omalizumab treatment intervals in patients with chronic spontaneous urticaria (EXOTIC trial) Ended

2023-506187-14-00 Chronic spontaneous urticaria 11 2024-01-12
A Phase 2 study to evaluate the efficacy and safety of SAR444656 compared with placebo in adult participants with moderate to severe hidrade… Ended

2023-504328-25-00 hidradenitis suppurativa 4 2023-12-27
A Phase 2 Multicenter Study to Evaluate PF-06823859 in Adult Participants With Active CLE or SLE With Cutaneous Manifestations Ended

2023-503343-33-00 Active Cutaneous Lupus Erythematosus (CLE) or Systemic 4 2023-12-21